Observational studyDrugs & aging2025
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients.
Observational study in Drugs & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveApixaban is the most prescribed direct-acting oral anticoagulant drug. According to its product information, clearance is only partially renal. However, little is known about the impact of renal function on apixaban pharmacokinetics in real-world settings. The aim of this study was therefore to investigate serum concentrations of apixaban in relation to renal function in acutely hospitalised, older patients.
methodsThe study was conducted with a prospective, observational design. Apixaban-treated patients ≥ 65 years acutely admitted to Haukeland University Hospital in Bergen, Norway, during a four-month period were included. Serum concentrations of apixaban were measured at hospitalization and assessed in relation to glomerular filtration rate (GFR). Spearman rank test was used to investigate correlation between GFR and dose-adjusted serum concentrations of apixaban. In addition, dose-adjusted serum concentrations were compared between GFR subgroups by Mann-Whitney tests.
resultsIn total, 36 patients were included (median age 84.5 years, range 68-96 years). Median GFR at admission was 43 ml/min (range 17-119 ml/min). Dose-adjusted apixaban serum concentrations correlated significantly with GFR (Spearman r = - 0.54, p = 0.0008). Compared with patients with GFR > 90 ml/min, apixaban dose-adjusted serum concentrations were 3.3-fold, 1.8-fold and 2.0-fold higher in patients with GFR < 30 ml/min (p = 0.01), 30-59 ml/min (p = 0.04) and 60-89 ml/min (n.s.), respectively.
conclusionsThe study shows that dose-adjusted serum concentration of apixaban significantly correlates with renal function in older, acute hospitalized patients. These real-life data indicate that apixaban-treated patients with GFR < 30 ml/min may require around 70% lower dose than normal to achieve sufficient antithrombotic effect and prevent risk of bleedings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.